Everstone-backed Integris Medtech has filed its DRHP with SEBI to raise ₹3,500–4,000 crore. The IPO includes a fresh issue plus promoter share sale, aiming to strengthen its balance sheet and fuel next-stage growth in the medical device sector.
Glimpse:
Integris Medtech, a rapidly growing diversified medtech platform in India, has taken a major step toward public listing by filing its Draft Red Herring Prospectus (DRHP) with SEBI. The IPO is set to raise between ₹3,500 and ₹4,000 crore, combining a fresh issue of about ₹925 crore with an offer for sale (OFS) by promoter shareholders. Proceeds will be used to repay debt, optimize capital structure, and support general corporate initiatives. The company counts operations in India, Germany, and the Netherlands, and markets devices globally. As India’s medtech market heats up, Integris’s entry may set the tone for innovation, consolidation, and investor confidence in the sector.
Big moves are afoot in India’s medtech space: Integris Medtech just filed with SEBI for an IPO that could raise between ₹3,500 and ₹4,000 crore. Backed by private equity firm Everstone, this is a play for scale, credibility, and deeper capital markets visibility.
Here’s how the structure looks: around ₹925 crore will come from a fresh equity infusion. In addition, promoter shareholders will offload a part of their stake through an offer for sale (OFS). These parallel threads allow the company to raise new funds while giving early backers a route toward liquidity.
Why now? Integris has been on an aggressive growth arc. Its footprints span India, Germany, and the Netherlands, and it sells medical devices and lab solutions to over 65 countries. Its product mix includes cardiovascular devices, diagnostics, and scientific lab tools. The IPO proceeds will help the company retire or prepay debt (especially in its subsidiaries), sharpen its balance sheet, and bankroll corporate expansion and innovation plans.
Performance so far paints a promising picture. In FY25, Integris’s total revenue grew significantly compared to the prior year, and the company swung from losses into profitability. This financial momentum gives the IPO narrative both investor appeal and strategic grounding.
Of course, challenges remain. The medtech sector is capital intensive, regulatory landscapes are complex, global competition stiff, and execution across geographies requires discipline. But with an IPO, Integris gains not only capital but scrutiny, governance expectations, and broader market confidence.
For the Indian medtech ecosystem, this move is noteworthy. IPOs raise the bar because public markets demand transparency, quality, and scale. A successful listing could inspire peers and draw greater investor interest into medtech, merging innovation with infrastructure in health.
“Filing the DRHP is a statement of intent we want to combine the capital edge of public markets with our mission to drive medtech breakthroughs at scale,”
By
HB Team
